• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Invizyne Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    2/11/25 5:27:46 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IZTC alert in real time by email
    false --12-31 0002010788 0002010788 2025-02-10 2025-02-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

    Current Report Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):

    February 10, 2025

     

    EXOZYMES INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-42204   83-4550057

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    750 Royal Oaks Drive, Suite 106

    Monrovia, CA 91016

    (Address of principal executive offices and zip code)

     

    Registrant’s telephone number, including area code: (626) 415-1488

     

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Exchange Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   EXOZ   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On February 10, 2025, Invizyne Technologies Inc. filed a certificate of amendment to its articles of incorporation to change its name to “eXoZymes Inc.”

     

    Item 9.01 — Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
         
    3.1*   Certificate of Amendment to the Articles of Incorporation filed February 10, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    * Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: February 11, 2025 EXOZYMES INC.
         
      By /s/ Fouad Nawaz
        Fouad Nawaz,
        Vice President, Finance

     

     

     

    Get the next $IZTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IZTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IZTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Heltzen Michael bought $20,345 worth of shares (1,888 units at $10.78), increasing direct ownership by 95% to 3,872 units (SEC Form 4)

    4 - Invizyne Technologies Inc (0002010788) (Issuer)

    1/21/25 6:02:17 AM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Heltzen Michael bought $22,022 worth of shares (1,984 units at $11.10) (SEC Form 4)

    4 - Invizyne Technologies Inc (0002010788) (Issuer)

    11/19/24 6:45:00 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IZTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Heltzen Michael bought $20,345 worth of shares (1,888 units at $10.78), increasing direct ownership by 95% to 3,872 units (SEC Form 4)

    4 - Invizyne Technologies Inc (0002010788) (Issuer)

    1/21/25 6:02:17 AM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Heltzen Michael bought $22,022 worth of shares (1,984 units at $11.10) (SEC Form 4)

    4 - Invizyne Technologies Inc (0002010788) (Issuer)

    11/19/24 6:45:00 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Bell Lon E

    3 - Invizyne Technologies Inc (0002010788) (Issuer)

    11/19/24 2:37:27 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IZTC
    SEC Filings

    View All

    Invizyne Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - EXOZYMES INC. (0002010788) (Filer)

    2/11/25 5:27:46 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invizyne Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Invizyne Technologies Inc (0002010788) (Filer)

    11/18/24 4:45:36 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IZTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes

    Rebranding Invizyne Technologies, Inc to eXoZymes Inc.Changing NASDAQ ticker from IZTC to EXOZIntroducing but not trademarking "exozymes" as a new scientific nomenclature Monrovia, California, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc. - a pioneer of AI-engineered enzymes that can sustainably transform feedstock into essential chemicals, medicines, and biofuels, announced a corporate name change to eXoZymes, Inc. ("eXoZymes") and that its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol of "EXOZ" effective before the market open. No action is required by existing shareholders with respect to the name and ticker symbol c

    2/12/25 8:50:00 AM ET
    $IZTC
    $MDBH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Finance: Consumer Services
    Finance

    Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

    Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced a corporate name change to eXoZymes, Inc. ("eXoZymes") and an application for a new ticker symbol. The company expects trading under the new ticker symbol of "EXOZ" to begin on February 12, 2025, subject to final approvals. In connection with the corporate name change, Company branding, including the corporate website, will be updated accordingly. No action is required by existing shareholders with respect to the name and

    2/10/25 11:00:00 AM ET
    $IZTC
    $MDBH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Finance: Consumer Services
    Finance

    Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities

    Monrovia, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced it was awarded a $2 million project to enable enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF). The project is a cost share grant from the U.S. Department of Defense's BioMADE initiative, in partnership with the University of Georgia. It is one of 17 BioMADE projects announced on October 30, 2024, to drive the scale-up and commercialization of American biomanufactured products. "The nex

    11/19/24 9:05:00 AM ET
    $IZTC
    $MDBH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Finance: Consumer Services
    Finance

    $IZTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Invizyne Technologies Inc.

    SC 13D - Invizyne Technologies Inc (0002010788) (Subject)

    11/18/24 7:58:02 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Invizyne Technologies Inc.

    SC 13D - Invizyne Technologies Inc (0002010788) (Subject)

    11/18/24 7:58:02 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Invizyne Technologies Inc.

    SC 13D - Invizyne Technologies Inc (0002010788) (Subject)

    11/18/24 7:58:02 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care